Aadil Najeed, Senior Resident of Government Medical College Srinagar, shared a post on LinkedIn:
“Systematic Overkill Illusion of De-escalation.
The recent data on Locally Advanced Rectal Cancer (LARC) with clear Mesorectal Fascia (MRF) presents a provocative clinical dilemma. While the headline numbers suggest parity, the underlying “pharmacologic logic” deserves a closer look.
The Data at a Glance (N=663).
A comparison between nCAPOX x 4 and nCRT revealed:
- LRRFS: 96.3% vs 97.4% (Non-inferiority not established).
- 3-Year DFS: 89.2% vs 87.9% (p=NS).
- 3-Year OS: 95% vs 94% (p=NS).
The Hidden Trade-off:
While the survival outcomes appear similar, we must look beyond the percentages. The trial essentially compensates for the omission of Radiation Therapy (RT) by escalating systemic chemotherapy.
In the nCRT arm, roughly 25% of patients never received multiagent chemotherapy, whereas the experimental arm mandated it for all. Achieving similar DFS/OS (even in N2 disease) is remarkable, but it raises a critical question about precision.
Precision or Collateral Damage?
Escalating systemic treatment to de-escalate local therapy may be counterintuitive. By replacing a targeted, focal treatment (RT) with increased cycles of systemic cytotoxics, we:
- Increase the volume of distribution.
- Expose healthy tissue body-wide to potential toxicity.
- Risk greater systemic harm to avoid treating a specific site.
The takeaway: True de-escalation should reduce the total burden of treatment, not simply shift the toxicity from a focal point to the entire body.”
Title: Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial
Authors: Wei-Jian Mei, Xiao-Zhong Wang, Yun-Feng Li, Yue-Ming Sun, Chun-Kang Yang, Jun-Zhong Lin, Zu-Guang Wu, Rui Zhang, Wei Wang, Yong Li, Ye-Zhong Zhuang, Jian Lei, Xiang-Bin Wan, Ying-Kun Ren, Yong Cheng, Wen-Liang Li, Zi-Qiang Wang, Dong-Bo Xu, Xian-Wei Mo, Hai-Xing Ju, Sheng-Wei Ye, Jing-Lin Zhao, Hong Zhang, Yuan-Hong Gao, Zhi-Fan Zeng, Wei-Wei Xiao, Xiao-Peng Zhang, Xuan Zhang, E Xie, Yi-Fei Feng, Jing-Hua Tang, Xiao-Jun Wu, Gong Chen, Li-Ren Li, Zhen-Hai Lu, De-Sen Wan, Jin-Xin Bei, Zhi-Zhong Pan and Pei-Rong Ding
Other articles featuring Aadil Najeed on OncoDaily.